The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determ...
Zapisane w:
| Główni autorzy: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
MDPI AG
2022-03-01
|
| Seria: | Tropical Medicine and Infectious Disease |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.mdpi.com/2414-6366/7/3/51 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|